Signatera™ helps monitor for cancer recurrence
Signatera™ is ordered by your doctor as part of your care
Signatera™ is a personalized blood test that detects small fragments of cancer DNA in your body. It provides additional information to you and your doctor, alongside imaging and other tests, to help guide your care.
How Signatera™ may be used
Signatera™ is a personalized molecular residual disease (MRD) test designed to provide important clinical insights at different points along your care pathway:
Detect molecular residual disease after treatment
Identify whether there are signs of residual disease after surgery or therapy
Guide treatment decisions
Help determine whether additional treatment may be beneficial
Monitor treatment response
Gain further insights into how your cancer is responding to therapy over time
Detect recurrence
Identify signs that cancer may be returning, potentially earlier than standard of care tools
Learn how Signatera™ works
Watch a short overview of how Signatera™ is designed to monitor for molecular residual disease.
Signatera™ is designed specifically for you, based on your unique tumor.
1. Personalized to your tumor
Your tumor sample is analyzed to identify DNA markers that are unique to your cancer
2. Blood testing over time
A simple blood draw is used to look for those same markers in your bloodstream at different points in your care
3. Results for your care team
Your doctor reviews your results alongside imaging and other tests to help guide your treatment plan
Talk with your healthcare provider about whether Signatera™ is right for you
Signatera™ must be ordered by a licensed healthcare provider. Your healthcare provider can help determine whether this type of testing fits into your care plan.
Hear from patients about their experience
Every cancer journey is different. These stories reflect how Signatera™ has been used as part of patient care.
Anj, living with breast cancer
Anj’s care team uses Signatera™ to help monitor her cancer over time
Dr. James Duke, head & neck cancer patient
Signatera™ was used as part of Dr. Duke’s monitoring during and after treatment
Amanda, after colorectal cancer treatment
Amanda’s doctor uses Signatera™ to help keep her informed as she moves forward
Learn more about Signatera™
Get information to help you understand whether Signatera™ may be appropriate for your care.
Support throughout your care
Signatera™ is ordered and managed by your healthcare provider
Insurance and billing support are available, including a financial assistance program for eligible patients
Our team can help answer general questions
Frequently asked questions
What is Signatera™?
Signatera™ is a personalized blood test that looks for small amounts of cancer DNA in your body. It is designed using your tumor to track changes over time and provide additional information to you and your doctor.
Who can use Signatera™?
Signatera™ may be used for patients who have been diagnosed with certain types of cancer. Your doctor will determine if it is appropriate for your situation.
Can I request Signatera™ myself?
No. Signatera™ must be ordered by your doctor. You can use the discussion guide to help start a conversation.
Is Signatera™ used to diagnose cancer?
No. It is used after diagnosis as part of ongoing care.
Is Signatera™ a replacement for scans?
No. It is used alongside imaging and other tools.
Does insurance cover Signatera™?
Signatera™ is covered by Medicare for monitoring disease progression, recurrence, or relapse in patients with:
- Stage II–IV and oligometastatic colorectal cancer (CRC) in the adjuvant and recurrence monitoring settings
- Muscle-invasive bladder cancer (MIBC) in the adjuvant and recurrence monitoring settings
- Stage II–IV breast cancer in the neoadjuvant setting, regardless of subtype
- Stage IIb and higher breast cancer in the adjuvant and recurrence monitoring settings
- Stage I–III non-small cell lung cancer (NSCLC) in the surveillance setting
- Stage II–IV ovarian, fallopian tube, or primary peritoneal cancer in the adjuvant and recurrence monitoring settings
- Monitoring response to immune checkpoint inhibitor (ICI) therapy in patients with any solid tumor
Natera works with most commercial insurance plans. Coverage varies based on your specific plan and clinical situation. For eligible patients, Natera offers financial assistance programs to help ensure cost is not a barrier to testing.
Test Limitations: Signatera™ can only be ordered by a physician or other authorized healthcare provider. This test provides information to be used alongside other clinical findings; it does not indicate definitively the presence or absence of cancer and it is not intended for diagnosis of cancer. It does not replace professional medical advice. Individual results and clinical management can vary. For additional information on test usage and limitations, visit Natera.com or speak with your doctor. This test is not designed to detect or report germline variation, nor does it infer hereditary cancer risk for the patient.
The test is a Laboratory Developed Test (LDT) performed in Natera’s CAP-accredited and CLIA-certified laboratories (CLIA ID 05D1082992, 05D1082992) and its performance characteristics were determined by Natera, Inc. The test has not been cleared or approved by the U.S. Food and Drug Administration (FDA).